Our novel selenium-based topical small-molecule medication is not toxic and safe in studies run to date.

​

Stable and non-toxic compound in tests run to date. 

• No loss of cell viability.

• No loss of metabolic function.

• Enhanced migration of fibroblast cells, which contributes to skin-tissue repair.

• No significant upregulation of (Se-dependent) thioredoxin reductase, or glutathione peroxidase at either protein or activity levels. 

• Protects human coronary artery endothelial cells against oxidative damage.

• No sign of inflammation or adverse effects when applied topically on mouse skin wounds in wild-type and diabetic mice. Improves wound healing.

• Oral dosing of mice over a 12-week period:

  • does not alter consumption of drinking water;

  • no change to body weight;

  • no weight gain over time;

  • no overt signs of distress or discomfort;

  • no noticeable behavioural changes.

• The therapeutic agent remains intact following treatment, with no obvious metabolites observed in plasma or tissue.

• No obvious signs of overt toxicity to liver or kidneys.

• No inflammatory-marker changes in mouse plasma. 

• Human and veterinary applications.